Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

  1. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection.Ann Intern Med. 2002 Dec 17;137(12):961-4.

  2. Apolinario A, Majano PL, Alvarez-Perez E, Saez A, Lozano C, Vargas J, Garcia Monzon C. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol. 2002 Nov;97(11):2861-70.

  3. Barash J, Dushnitzky D, Sthoeger D, Bardenstein R, Barak Y.  Human parvovirus B19 infection in children: uncommon clinical presentations. Isr Med Assoc J. 2002 Oct;4(10):763-5.

  4. Bergamini A, Cepparulo M, Bolacchi F, Araco A, Tisone G, Ombres D, Rocchi G, Angelico M. Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.Clin Exp Immunol. 2002 Nov;130(2):293-9.

  5. Boyle BA. Recent research in HIV infection, part 2. AIDS Read. 2002 Dec;12(12):524-6, 539.

  6. Chang YC, Ho CL, Chen HH, Chang TT, Lai WW, Dai YC, Lee WY, Chow NH. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum.Br J Cancer. 2002 Dec 2;87(12):1449-53.

  7. Clark CH, Mahoney JS, Clark DJ, Eriksen LR. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D).J Adv Nurs. 2002 Nov;40(3):361-9.

  8. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S145-51.

  9. Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, Coulaud JP, Vilde JL, Vachon F, Degott C, Valla D, Marcellin P.  Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.Gastroenterology. 2002 Dec;123(6):1812-22.

  10. Diment J, Calmann M. Alternatives to nucleic acid testing in the blood transfusion service.Lancet. 2002 Nov 9;360(9344):1518-9; author reply 1519-20.

  11. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002 Nov;36(5 Suppl 1):S210-9.

  12. Fleming J. Current treatments for hepatitis. J Infus Nurs. 2002 Nov-Dec;25(6):379-82.

  13. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S57-64.

  14. Forns X, Ampurdanes S, Llovet JM,Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002 Oct;36(4 Pt 1):986-92.

  15. Hagan H, Thiede H, McGough JP, Alexander ER. Hepatitis B vaccination among research participants, Seattle, Washington. Am J Public Health. 2002 Nov;92(11):1756.

  16. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002 Nov;36(5):1206-13.

  17. Izumi Y, Kaneko A, Oku K, Kimura M, Tanaka S, Tada H, Tatsumi K, Takano T, Hidaka Y, Amino N. Development of liver dysfunction after delivery is possibly due to postpartum autoimmune hepatitis. A report of three cases. J Intern Med. 2002 Oct;252(4):361-7.

  18. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002 Oct;123(4):1070-83.

  19. Kanno A, Kazuyama Y. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection. J Med Virol. 2002 Oct;68(2):229-33.

  20. Kawai S, Yokosuka O, Imazeki F, Saisho H, Mizuno C. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level. J Med Virol. 2002 Nov;68(3):343-51.

  21. Kobayashi T, Sugawara Y, Shi YZ, Makuuchi M. Telomerase expression and p53 status in hepatocellular carcinoma. Am J Gastroenterol. 2002 Dec;97(12):3166-71.

  22. Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002 Dec 9-23;162(22):2545-56.

  23. Leifeld L, Cheng S, Ramakers J, Dumoulin FL, Trautwein C, Sauerbruch T, Spengler U.  Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology. 2002 Oct;36(4 Pt 1):1001-8.

  24. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S47-56.

  25. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C.  Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 2002 Dec 15;95(12):2539-45.

  26. McCulloch M, Broffman M, Gao J, Colford JM Jr. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Am J Public Health. 2002 Oct;92(10):1619-28.

  27. Menon Y, Singh R, Cuchacovich R, Espinoza LR. Pulmonary involvement in hepatitis B-related polyarteritis nodosa. Chest. 2002 Oct;122(4):1497-8.

  28. Nikolova M, Liubomirova M, Iliev A, Krasteva R, Andreev E, Radenkova J, Minkova V, Djerassi R, Kiperova B, Vlahov ID.  Clinical significance of antinuclear antibodies, anti-neutrophil cytoplasmic antibodies and anticardiolipin antibodies in heroin abusers. Isr Med Assoc J. 2002 Nov;4(11 Suppl):908-10.

  29. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.Ann Intern Med. 2002 Dec 17;137(12):947-54.

  30. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S65-73.

  31. Pol S, Lebray P.N-acetylcysteine for paracetamol poisoning: effect on prothrombin. Lancet. 2002 Oct 12;360(9340):1115.

  32. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, Trepo C.  Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002 Oct;36(4 Pt 1):973-7.

  33. Prokurat A, Kluge P, Chrupek M, Kosciesza A, Rajszys P. Hemangioma of the liver in children: proliferating vascular tumor or congenital vascular malformation? Med Pediatr Oncol. 2002 Nov;39(5):524-9.

  34. Renou C, Pol S, Halfon P, Caillat-Zucman S. Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: what can be done about the present definition? Gastroenterology. 2002 Nov;123(5):1748-9

  35. Requena-Silla Y, Rosenfield CG, Miller LC.  Antiphospholipid antibodies and Down syndrome: a case series. J Pediatr Hematol Oncol. 2002 Oct;24(7):575-8.

Pathogenesis :

  1. Agnello V, Mecucci C, Casato M. Regression of splenic lymphoma after treatment of hepatitis C virus infection.N Engl J Med. 2002 Dec 26;347(26):2168-70

  2. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol. 2002 Nov;39(5):530-5.

  3. Cainelli F, Vento S.  Sequelae and serologic outcome in persons with hepatitis B virus infection. Ann Intern Med. 2002 Oct 1;137(7):619

  4. Cheney IW, Lai VC, Zhong W, Brodhag T, Dempsey S, Lim C, Hong Z, Lau JY, Tam RC. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons.J Virol. 2002 Nov;76(21):11148-54.

  5. Cooper CL, Cameron DW. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis. 2002 Oct 1;35(7):873-9.

  6. Diamond C, Lee JH. Use of antiviral therapy in patients with hepatitis C. Ann Intern Med. 2002 Dec 17;137(12):1012.

  7. Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):536-41.

  8. Guida M, D'Elia G, Benvestito S, Casamassima A, Micelli G, Quaranta M, Moschetta R, De Lena M, Lorusso V. Hepatitis C virus infection in patients with B-cell lymphoproliferative disorders.Leukemia. 2002 Oct;16(10):2162-3.

  9. Halkic N, Bally F, Gillet M. Organ transplantation in HIV-infected patients. N Engl J Med. 2002 Nov 28;347(22):1801-3

  10. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, Mueller C, Gangl A, Ferenci P.  Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol. 2002 Nov;97(11):2880-5.

  11. Huang JW, Yen CJ, Pai MF, Wu KD, Tsai TJ, Hsieh BS. Association between serum aspartate transaminase and homocysteine levels in hemodialysis patients.Am J Kidney Dis. 2002 Dec;40(6):1195-201.

  12. Jacobs RJ, Meyerhoff AS, Koff RS. Re: Arguedas et al.--Hepatitis A prevention analysis.Am J Gastroenterol. 2002 Nov;97(11):2924-5

  13. Johnson B.Hepatitis C: be positively aware of the risk of transmission and treatment. Posit Aware. 2002 Nov-Dec;13(6):29-31.

  14. Labonte P, Axelrod V, Agarwal A, Aulabaugh A, Amin A, Mak P. Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure-based site-directed mutagenesis. J Biol Chem. 2002 Oct 11;277(41):38838-46.

  15. Loustaud-Ratti V, Liozon E, Karaaslan H, Alain S, Paraf F, Le Meur Y, Denis F, Vidal E.Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med. 2002 Oct 15;113(6):516-9.

  16. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol. 2002 Oct;17(10):1049-55.

  17. Osawa Y, Nagaki M, Banno Y, Brenner DA, Asano T, Nozawa Y, Moriwaki H, Nakashima S. Tumor necrosis factor alpha-induced interleukin-8 production via NF-kappaB and phosphatidylinositol 3-kinase/Akt pathways inhibits cell apoptosis in human hepatocytes. Infect Immun. 2002 Nov;70(11):6294-301.

  18. Pande H, Lacy BE, Crowell MD. Inflammatory causes of gastroparesis: report of five cases.Dig Dis Sci. 2002 Dec;47(12):2664-8.

  19. Qian GS, Kuang SY, He X, Groopman JD, Jackson PE. Sensitivity of electrospray ionization mass spectrometry detection of codon 249 mutations in the p53 gene compared with RFLP.Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1126-9.

  20. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, Espy MJ, Kremers W, Wilson JA, Groettum C, Wiesner R, Paya CV. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002 Oct 15;35(8):974-81.

  21. Ressel GW.CDC releases 2002 guidelines for treating STDs: Part II. Human papillomavirus and hepatitis. Am Fam Physician. 2002 Nov 15;66(10):1996, 1999.

  22. Rossi A, Renzetti D, D'Albenzio L, Gianfelice D, Kalyvoka A, Rinaldi O. Case of mania induced by withdrawal of interferon-alpha in a patient affected by bipolar disorder. Psychiatry Clin Neurosci. 2002 Dec;56(6):647-8.

  23. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002 Nov;76(21):11079-90.

  24. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002 Oct 1;166(7):916-9.

  25. Somjee S, Pai S, Parikh P, Banavali S, Kelkar R, Advani S.  Passive active prophylaxis against Hepatitis B in children with acute lymphoblastic leukemia. Leuk Res. 2002 Nov;26(11):989-92.

  26. Stancu M, Jones D, Vega F, Medeiros LJ.  Peripheral T-cell lymphoma arising in the liver. Am J Clin Pathol. 2002 Oct;118(4):574-81.

  27. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, Sakuta S.  Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology. 2002 Oct;36(4 Pt 1):1022.

  28. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002 Dec 14;360(9349):1921-6.

  29. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002 Nov;36(5 Suppl 1):S201-9.

  30. Tiffen L, Sheridan S. Improving take-up of hepatitis C services. Nurs Times. 2002 Oct 22-28;98(43):30-2.

  31. Welch KJ, Morse A. Improving screening and vaccination for hepatitis B in patients coinfected with HIV and hepatitis C. Am J Gastroenterol. 2002 Nov;97(11):2928-9.

  32. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust. 2002 Oct 21;177(8):440-3.

  33. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002 Nov;36(5 Suppl 1):S185-94.

  34. Yao N, Hong Z, Lau JY. Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy. Gastroenterology. 2002 Oct;123(4):1350-63.

  35. Young KC, Lin PW, Hsiao WC, Chang TT, Chang YC, Wu HL. Variation of hepatitis C virus load, hypervariable region 1 quasispecies and CD81 hepatocyte expression in hepatocellular carcinoma and adjacent non-cancerous liver. J Med Virol. 2002 Oct;68(2):188-96.

  36. Youssef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol. 2002 Oct;35(4):345-9.

  37. Zhu H, Wang SY, Zhang JY, Lian QZ, Peng XX.  Analysis of complement-bound HCV complexes using a novel immuno-capture RT-PCR method. Scand J Immunol. 2002 Nov;56(5):538-42.

Vaccines :

  1. Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S, Galle PR. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Clin Exp Immunol. 2002 Oct;130(1):107-14.